PROM1 and hepatocellular carcinoma: CD133-positive expression had shorter OS, disease-free survival, and recurrence-free survival than those with CD133-negative expression (P < .05).<h4>Conclusion</h4>This meta-analysis suggests that CD133 is a potential biomarker for predicting poor survival in Asian hepatocellular carcinoma patients, especially for OS.